Stock VHT VOLPARA HEALTH TECHNOLOGIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Volpara Health Technologies Limited

Equities

VHT

NZVHTE0001S6

Market Closed - Australian S.E.
Other stock markets
 02:10:52 2024-04-24 am EDT 		5-day change 1st Jan Change
1.14 AUD 0.00% Intraday chart for Volpara Health Technologies Limited 0.00% +3.17%
Apr. 12 Volpara Health Technologies Secures Approval for Lunit’s Proposed Takeover MT
Apr. 12 Transcript : Volpara Health Technologies Limited - Shareholder/Analyst Call

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 67% by 2026.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Most analysts recommend that the stock should be sold or reduced.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
VOLPARA HEALTH TECHNOLOGIES LIMITED Stock Volpara Health Technologies Limited
+3.17% 188M -
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+2.51% 32.41B
C
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+12.62% 7.31B
C-
SECTRA AB Stock Sectra AB
+20.38% 3.85B
B-
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-14.03% 3.33B
C-
OMNICELL, INC. Stock Omnicell, Inc.
-28.73% 1.26B
B
LUNIT INC. Stock Lunit Inc.
-34.43% 1.12B -
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
+1.03% 932M
C
VERADIGM INC. Stock Veradigm Inc.
-26.69% 864M -
C+
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-38.47% 863M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. VHT Stock
  4. Ratings Volpara Health Technologies Limited